MedPath

Collection of Cerebrospinal Fluid in Healthy Children

Terminated
Conditions
Batten Disease
Late Infantile Neuronal Ceroid Lipofuscinosis
Registration Number
NCT01698229
Lead Sponsor
Weill Medical College of Cornell University
Brief Summary

The purpose of this study is to obtain cerebrospinal fluid from healthy children already undergoing a lumbar puncture procedure at New York Presbyterian Hospital, to act as healthy controls when compared to children with late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal neurodegenerative disease.

Detailed Description

obtain cerebrospinal fluid from healthy children already undergoing a lumbar puncture procedure at New York Presbyterian Hospital, to act as healthy controls when compared to children with late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal neurodegenerative disease.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Males and females, ages 2 yrs to 8 yrs
  • Children already undergoing a lumbar puncture procedure for clinical or diagnostic purposes
Exclusion Criteria
  • Presence of any significant neurological diseases, as judged by the co-investigators
  • Presence of any significant medical conditions including cancer

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cerebrospinal fluid (CSF)1 time point (once)

The primary study endpoint is the metabolic profiling of 32 samples of cerebrospinal fluid from healthy subjects, in comparison to 32 samples of CSF from children with LINCL, to determine whether there are biomarkers found in the cerebrospinal fluid that are associated with LINCL.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Weill Cornell Medical College / New York Presbyterian Hospital

🇺🇸

New York, New York, United States

Weill Cornell Medical College / New York Presbyterian Hospital
🇺🇸New York, New York, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.